And single-cell analysis revealed that at OC recurrence, HRD and HRP tumors diverge: HRD tumors maintain the CD8+T cell-DC interaction niche to maintain immunogenicity, secret prostanoid E2 (PGE2) through the COX/PGE2 pathway to inhibit T cell proliferation and function and achieve immune evasion, whereas HRP tumors lose the CD8+T cell-DC interaction niche and accumulate TREM2+/ApoE+ TAMs (66).HRD and HRP recurrent OC have completely different immune escape mechanisms, and therefore require targeted therapeutic approaches. The gene discussed is CD8A; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.